IDEAYA Biosciences Valuation Multiples

IDEAYA Biosciences Overview

About IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Founded

2015

HQ

Employees

145

Website

ideayabio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $168M

EBITDA: ($224M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

IDEAYA Biosciences Financials

IDEAYA Biosciences reported last 12-month revenue of $168M and negative EBITDA of ($224M).

In the same LTM period, IDEAYA Biosciences generated $168M in gross profit, ($224M) in EBITDA losses, and had net loss of ($180M).

IDEAYA Biosciences P&L

In the most recent fiscal year, IDEAYA Biosciences reported revenue of $219M and EBITDA of ($155M).

IDEAYA Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences has current market cap of $3B, and enterprise value of $2B.

IDEAYA Biosciences' stock price is $31.00.

IDEAYA Biosciences Valuation Multiples

IDEAYA Biosciences trades at 12.5x EV/Revenue multiple, and (9.4x) EV/EBITDA.

IDEAYA Biosciences Financial Valuation Multiples

As of April 11, 2026, IDEAYA Biosciences has market cap of $3B and EV of $2B.

Equity research analysts estimate IDEAYA Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

IDEAYA Biosciences has a P/E ratio of (15.1x).

IDEAYA Biosciences Margins & Growth Rates

IDEAYA Biosciences' revenue in the last 12 month declined by (65%).

IDEAYA Biosciences' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $2.6M for the same period.

IDEAYA Biosciences' rule of 40 is (1220%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IDEAYA Biosciences' rule of X is (1346%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

IDEAYA Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

IDEAYA Biosciences M&A Activity

IDEAYA Biosciences acquired XXX companies to date.

Last acquisition by IDEAYA Biosciences was on XXXXXXXX, XXXXX. IDEAYA Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

IDEAYA Biosciences Investment Activity

IDEAYA Biosciences invested in XXX companies to date.

IDEAYA Biosciences made its latest investment on XXXXXXXX, XXXXX. IDEAYA Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).